Glycoconjugates for glucose transporter-mediated cancer-specific targeting and 
treatment

Fu, Junjie; Yang, Jiaxin; Seeberger, Peter H.; Yin, Jian

doi:10.1016/j.carres.2020.108195

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment

MPS-Authors

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger - Automated Systems, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Fu, J., Yang, J., Seeberger, P. H., & Yin, J. (2020). Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment. Carbohydrate Research, 498: 108195. doi:10.1016/j.carres.2020.108195.

Cite as: https://hdl.handle.net/21.11116/0000-0007-7E2B-D

Abstract

First observed in 1920s, the Warburg effects have inspired scientists to harness the unique glucose metabolism of cancer cells for targeted therapy for a century. Carbohydrate-drug conjugates are explicitly designed for selective uptake by cancer cells overexpressing glucose transporters. We summarize the progress in developing glycoconjugates for cancer-specific targeting and treatment over the past decade (2010–2020) and point to some future directions in this field.